Malta-based B2B generics developer and manufacturer Pharmacare Premium has claimed a leading position in developing a generic rival to Novartis’ Votrient (pazopanib) for the European market after completing key bioequivalence trials for the oncology drug.
Having begun developing generics just three years ago – and having since “successfully completed some co-development projects” – the specialist in high-potency oral solid dosage forms told Generics Bulletin that it had just successfully completed two bioequivalence studies for a generic version of
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?